drugset / Trial / NCT00977561

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

NCT00977561

Phase 2 Terminated 9 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.

Timeline

Start
2010-04
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Figitumumab Monoclonal antibody 20 mg/kg
Comparator Carboplatin Small molecule 5 unknown
Comparator Cisplatin Other / unclassified 75 mg/m2 Intravenous
Comparator Etoposide Small molecule 100 mg/m2 Intravenous